Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability: Interplay between the N-Terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of α -Aminoacyl-L-cis-4,5-methanoprolinenitrile-Based Inhibitors

Journal of Medicinal Chemistry

Volumn 47, Issue 10, 2004, Pages 2587-2598

  Magnin, David R ^a   Robl, Jeffrey A ^a   Sulsky, Richard B ^a   Augeri, David J ^a,b   Huang, Yanting ^a   Simpkins, Ligaya M ^a   Taunk, Prakash C ^a   Betebenner, David A ^a,c   Robertson, James G ^a   Abboa Offei, Benoni E ^a   Wang, Aiying ^a   Cap, Michael ^a   Xin, Li ^a   Tao, Li ^a   Sitkoff, Doree F ^a   Malley, Mary F ^a   Gougoutas, Jack Z ^a   Khanna, Ashish ^a   Huang, Qi ^a   Han, Song Ping ^a   Parker, Rex A ^a   Hamann, Lawrence G ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

^b LEXICON PHARMACEUTICALS INC   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINOACYL 4,5 METHANOPROLINENITRILE DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; NITRILE; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALYSIS; CONTROLLED STUDY; CYCLIZATION; DRUG ACTIVITY; DRUG POTENCY; DRUG STABILITY; DRUG SYNTHESIS; INSULIN RELEASE; MALE; MOLECULAR STABILITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN DEGRADATION; RAT STRAIN;

ANIMALS; ANTIGENS, CD26; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; CYCLOPROPANES; DIPEPTIDES; DRUG STABILITY; ENZYME INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR MIMICRY; NITRILES; PROLINE; RATS; RATS, ZUCKER; SOLUTIONS;

EID: 2342565117     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049924d     Document Type: Article

References (91)

1. (a) King, H.; Aubert, R. E.; Herman, W. H. Global Burden of Diabetes, 1995-2025: Prevalence, Numerical Estimates and Projections. Diabetes Care 1998, 21, 1414-1431.
2. (b) Wagman, A. S.; Nuss, J. M. Current Therapies and Emerging Targets for the Treatment of Diabetes. Curr. Pharm. Des. 2001, 7, 417-450.
3. (c) Harris, M. I.; Hadden, W. C.; Knowler, W. C.; Bennet, P. H.; Prevalence of Diabetes and Impaired Glucose Tolerance and Plasma Glucose Levels in U.S. Population Aged 20-74 yr. Diabetes 1987, 36, 523-534.
4. (a) Saltiel, A. R.; Olefsky, J. M. Thiazolidinediones in the Treatment of Insulin Resistance and Type H Diabetes. Diabetes 1996, 45, 1661-1669.
5. (b) Schoonjans, K.; Martin, G.; Staels, B.; Auwerx, J. Peroxisome Proliferator-Activated Recepters, Orphans with Ligands and Functions. Curr. Opin. Lipidol. 1997, 8, 159-166.
6. (c) Pittas, A. G.; Greenberg, A. S.; Thiazolidinediones in the Treatment of Type 2 Diabetes. Expert Opin. Pharmacother. 2002, 3, 529-540.
7. (d) Rami, H. K.; Smith, S. A.; Synthetic Ligands for PPARγ-Review of Patent Literature 1994-1999. Expert Opin. Ther. Pat. 2000, 10, 623-634.
8. (e) Van Gaal, L.; Scheen, A. J. Are All Glitazones the Same? Diabetes Metab. Res. Rev. 2002, 18, S1-S4.
9. (f) Hauner, H. The Mode of Action of Thiazolidinediones. Diabetes Metab. Res. Rev. 2002, 18, S10-S15.
10. (a) Rosenstock, J.; Schwartz, S. L.; Clark, C. M., Jr.; Park, G. D.; Donley, D. W.; Edwards, M. B. Basal Insulin Therapy in Type 2 Diabetes: 28-Week Comparison of Insulin Glargine (HOE 901) and NPH Insulin. Diabetes Care 2001, 24, 631-636.
11. (b) Barnett, A. H.; Owens, D. R. Insulin Analogues. Lancet 1997, 349, 47-51.
12. (a) Anonymous. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS) 13: Relative Efficacy of Randomly Allocated Diet, Sulphonylurea, Insulin, or Metformin in Patients with Newly Diagnosed Non-Insulin Dependent Diabetes Followed for Three Years. Br. Med. J. 1995, 310, 83-88.
13. (b) U.K. Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 7: Response of Fasting Plasma Glucose to Diet Therapy in Newly Presenting Type II Diabetic Patients. Metabolism 1990, 39, 905-912.
14. (c) Gerich, J. E. Oral Hypoglycemic Agents. N. Engl. J. Med. 1989, 321, 1231-1245.
15. (a) Witters, L. The Blooming of the French Lilac. J. Clin. Invest. 2001, 108, 1105-1107.
16. (b) Bailey, C. J.; Path, M. R. C.; Turner, R. C. Metformin N. Engl. J. Med. 1996, 334, 574-579.
17. (a) Lillelund, V. H.; Jensen, H. H.; Liang, X.; Bols, M. Recent Developments of Transition-State Analogue Glycosidase Inhibitors of Non-Natural Product Origin. Chem. Rev. 2002,102, 515-553.
18. (b) Berecibar, A.; Grandjean, C.; Siriwardena, A. Synthesis and Biological Activity of Natural Aminocyclopentitol Glycosidase Inhibitors: Mannostatins, Trehazolin, Allosamidins, and Their Analogs. Chem. Rev. 1999, 99, 779-844.
19. (c) Jacob, G. S. Glycosylation Inhibitors in Biology and Medicine. Curr. Opin. Struct. Biol. 1995, 5, 605-611.
20. (a) Holst, J. J. Glucagon-Like Peptide-1 (GLP-1) a Newly Discovered GI Hormone. Gastroenterology 1994, 107, 1048-1055.
21. (b) Orsakov, C. Glucagon-Like Peptide-1, a New Hormone of the Enteroinsular Axis. Diabetologia 1992, 35, 701-711.
22. (c) Drucker, D. J. Glucagon-Like Peptides. Diabetes 1998, 47, 159-169.
23. (a) Nauck, M. A.; Kleine, N.; Orskov, C.; Holst, J. J.; Willms, B.; Creutzfeldt, W. Normalization of Fasting Hyperglycaemia by Exogenous Glucagon-Like Peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) Diabetic Patients. Diabetologia 1993, 36, 741-744.
24. (b) Nauck, M. A.; Wollschlager, D.; Werner, J.; Holst, J. J.; Orskov, C. ; Creutzfeldt, W.; Willms, B. Effects of Subcutaneous Glucagon-Like Peptide 1 (GLP-1 [7-36 amide] in Patients with NIDDM. Diabetologia 1996, 39, 1546-1553.
25. (c) Toft-Nielsen, M. B.; Madsbad, S.; Holst, J. J. Continuous Subcutaneous Infusion of Glucagon-Like Peptide 1 (7-36) Amide Lowers Plasma Glucose and Reduces Appetite in Type 2 Diabetic Patients. Diabetes Care 1999, 22, 1137-1143.
26. (d) Juhl, C. B.; Hollingdal, M.; Sturis, J.; Jakobsen, G.; Agerso, H.; Veldhuis, J.; Porksen, N.; Schmitz, O. Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes. Diabetes 2002, 51, 424-429.
27. (e) Kolterman, O. G.; Buse, J. B.; Fineman, M. S.; Gaines, E.; Heintz, S.; Bicsak, T. A.; Taylor, K.; Kim, D.; Aisporna, M.; Wang, Y.; Baron, A. D. Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2003, 88, 3082-3089.
28. (a) Wettergren, A.; Wojdemann, M.; Holst, J. J. The Inhibitory Effect of Glucagon-Like Peptide-1 (7-36) Amide on Antral Motility Is Antagonized by its N-Terminally Truncated Primary Metabolite GLP-1 (9-36) Amide. Peptides 1998, 19 (5), 877-882.
29. (b) Knudsen, L. B.; Pridal, L. Glucagon-Like Peptide-1 (9-36) Amide Is a Major Metabolite of Glucagon-Like Peptide-1 (7-36) Amide after in Vivo administration to Dogs, and It Acts as an Antagonist on the Pancreatic Receptor. European J. Pharmacol. 1996, 318, 429-435.
30. (a) Hansen, L.; Deacon, C. F.; Orskov, C.; Holst, J. J. Glucagon-Like Peptide-1 (7-36) Amide Is Transformed to Glucagon-Like Peptide-1 (9-36) Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L-Cells of the Porcine Intestine. Endocrinology 1999, 140, 5356-5363.
31. (b) Kieffer, T. J.; McIntosh, C. H. S.; Pederson, R. A. Degradation of Glucose-Dependent Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide-1 in Vitro and in Vivo by Dipeptidyl Peptidase IV. Endocrinology 1995, 136, 3585-3597.
32. (a) Drucker, D. J. Therapeutic Potential of Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes. Expert Opin. Invest. Drugs 2003, 12, 87-96.
33. (b) Augustyns, K.; Van der Veken, P.; Senten, K.; Haemers, A. Dipeptidyl Peptidase IV Inhibitors as New Therapeutic Agents for the Treatment of Type 2 Diabetes. Expert Opin. Ther. Pat. 2003, 13, 499-510.
34. (c) Zhang, B. B.; Moller, D. E. New Approaches in the Treatment of Type 2 Diabetes. Curr. Opin. Chem. Biol. 2000, 4, 461-467.
35. (d) Holst, J. J.; Deacon, C. F. Perspectives in Diabetes: Inhibition of the Activity of Dipeptidyl-Peptidase IV as a Treatment for Type 2 Diabetes. Diabetes 1998, 47, 1663-1670.
36. (e) Hildebrandt, M.; Reutter, W.; Arck, P.; Rose, M.; Klapp, B. F. A Guardian Angel: The Involvement of Dipeptidyl Peptidase IV in Psychoneuroendocrine Function, Nutrition and Immune Defence. Clin. Sci. 2000, 99, 93-104.
37. Additional studies in DPP-IV knockout animals have supported these findings: (f) Marguet, D.; Baggio, L.; Kobayashi, T.; Bernard, A.-M.; Pierres, M.; Nielsen, P. F.; Ribel, U.; Watanabe, T.; Drucker, D. J.; Wagtmann, N. Enhanced Insulin Secretion and Improved Glucose Tolerance in Mice Lacking CD26. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 6864-6879.
38. (g) Nagakura, T.; Yasuda, N.; Yamazaki, K.; Ikuta, H.; Yoshikawa, S.; Asano, O.; Tanaka, I. Improved Glucose Tolerance via Enhanced Glucose-Dependent Insulin Secretion in Dipeptidyl Peptidase IV-Deficient Fischer Rats. Biochem. Biophys. Res. Commun. 2001, 284, 501-506.
39. (a) Coutts, S. J.; Kelly, T. A.; Snow, R. J.; Kennedy, C. A.; Barton, R. W.; Adams, J.; Krolikowski, D. A.; Freeman, D. M.; Campbell, S. J.; Ksiazek, J. F.; Bachovchin, W. W. Structure-Activity Relationships of Boronic Acid Inhibitors of Dipeptidyl Peptidase IV. 1. Variation of the P2 Position of Xaa-boroPro Dipeptides. J. Med. Chem. 1996, 39, 2087-2094.
40. (b) Wallner, B. Inhibitors of Dipeptidyl Peptidase IV (DPP-IV) for Regulation of Substrate Activity and Therapeutic Use. PCT Int. Appl. WO 0010549 A1, 2000 (38 pages).
41. (c) Huber, B. T.; Schmitz, T. Underwood, R. Potentiation of the Immune Response through Delivery of Compounds Binding a Cytoplasmic Dipeptidase. PCT Int. Appl. WO 9850066 A1, 1998 (26 pages).
42. (a) Senten, K.; Van der Veken, P.; Bal, G.; Haemers, A.; Augustyns, K. Polymer-Assisted Solution-Phase Parallel Synthesis of Dipeptide p-Nitroanilides and Dipeptide Diphenylphosphonates. Tetrahedron Lett. 2001, 42, 9135-9138.
43. (b) Belyaev, A.; Borloo, M.; Augustyns, K.; Lambeir, A.-M.; De Meester, I.; Scharpe, S.; Blaton, N.; Peeters, O. M.; De Ranter, C.; Haemers, A. A New Synthetic Method for Proline Diphenylphosphonates. Tetrahedron Lett. 1995, 36, 3755-3758.
44. (a) Ashworth, D. M.; Atrash, B.; Baker, G. R.; Baxter, A. J.; Jenkins, P. D.; Jones, D. M.; Szelke, M. 2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV. Bioorg. Med. Chem Lett. 1996, 6, 1163-1166.
45. (b) Jenkins, P. D.; Jones, D. M.; Szelke, M. Preparation of Peptide Analog DP-IV Serine Protease Inhibitors. PCT Int. Appl. WO 9515309 Al, 1995 (55 pages).
46. (a) Villhauer, E. B. Preparation of 1-Glycyl-2-cyanopyrrolidines as Dipeptidyl Peptidase-IV Inhibitors. U.S. 6011155 A, 2000 (20 pages).
47. (b) Hughes, T. E.; Mone, M. D.; Russell, M. E.; Weldon, S. C.; Villhauer, E. B. NVP-DPP728 (1-[[[2-[(5-Cyanopyridin-2-yl)amino]ethyl]amino] acetyl]-2-cyano-(S)-pyrrolidine), a Slow-Binding Inhibitor of Dipeptidyl Peptidase IV. Biochemistry 1999, 38, 11597-11603.
48. (c) Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Dunning, B. E.; Mangold, B. L.; Mone, M. D., Russell, M. E.; Weldon, S. C.; Hughes, T. E. 1-[2-[(5-Cycanopyridine-2-yl)amino]ethylamino]acety]-2-(S) -pyrrolidine-carbonitrile: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties. J. Med. Chem. 2002, 45, 2362-2365.
49. Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Burkey, B. F.; Dunning, B. E.; Prasad, K.; Mangold, B. L.; Russell, M. E.; Hughes, T. E. 1-[[3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties. J. Med. Chem. 2003, 46, 2774-2789.
50. (a) Sorbera, L. A.; Revel, L.; Castaner, J. P32/98: Antidiabetic Dipeptidyl-Peptidase IV Inhibitor. Drugs Future 2001, 26, 859-864.
51. (b) Pauly, R. P.; Demuth, H.-U.; Rosche, F.; Schmidt, J.; White, H. A.; Lynn, F.; McIntosh, C. H. S.; Pederson, R. A. Improved Glucose Tolerance in Rats Treated with the Dipeptidyl Peptidase IV (CD26) Inhibitor Ile-thiazolidide. Metab., Clin. Exp. 1999, 48, 385-389.
52. (c) Pederson, R. A.; White, H. A.; Schlenzig, D.; Pauly, R. P.; McIntosh, C. H. S.; Demuth, H.-U. Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide. Diabetes 1998, 47, 1253-1258.
53. Some very recent notable exceptions to this trend of reduced potency in dipeptide-based inhibitors lacking a nitrile moiety can be found in the following references from the Merck group: (d) Parmee, E. R.; He, J.; Mastracchio, A.; Edmondson, S. D.; Colwell, L.; Eiermann, G.; Feeney, W. P.; Habulihaz, B.; He, H.; Kilburn, R.; Leiting, B.; Lyons, K.; Marsilio, F.; Patel, R. A.; Petrov, A.; Di Salvo, J.; Wu, J. K.; Thornberry, N. A.; Weber, A. E. 4-Aminocyclohexylglycine Analogues as Potent Dipeptidyl Peptidase IV Inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 43-46.
54. (e) Ashton, W. T.; Dong, H.; Sisco, R. M.; Doss, G. A.; Leiting, B.; Patel, R. A.; Wu, J. K.; Marsilio, F.; Thornberry, N. A.; Weber, A. E. Diastereoselective Synthesis and Configuration-Dependent Activity of (3-Substituted-cycloalkyl)glycine Pyrrolidides and Thiazolidides as Dipeptidyl Peptidase IV Inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 859-863.
55. (f) Caldwell, C. G.; Chen, P.; He, J.; Parmee, E. R.; Leiting, B.; Marsilio, F.; Patel, R. A.; Wu, J. K.; Eiermann, G. J.; Petrov, A.; He, H.; Lyons, K. A.; Thornberry, N. A.; Weber, A. E. Fluoropyrrolidine Amides as Dipeptidyl Peptidase IV Inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 1265-1268.
56. (a) Hanessian, S.; Reinhold, U.; Saulnier, M.; Claridge, S. Probing the Importance of Spatial and Conformational Domains in Captopril Analogs for Angiotensin Converting Enzyme Activity. Bioorg. Med. Chem. Lett. 1998, 8, 2123-2128.
57. (b) Hanessian, S.; Reinhold, U.; Gentile, G. The Synthesis of Enantiopure ω-Methanoprolines and ω-Methanopipecolic Acids by a Novel Cyclopropanation Reaction: The "Flattening" of Proline. Angew. Chem., Int. Ed. Engl. 1997, 36, 1881-1884.
58. (a) Sasaki, N. A.; Sagnard, I.; Ciaroni, A.; Riche, C.; Potier, P. Enantioselective Synthesis of Cyclopropane α-Amino Acids: Synthesis of N-Boc-cis-(2S,3R,4S)-3,4-Methanoproline and N-Boc-(2S,3R,4S)-3, 4-Methanoglutamic Acid. Tetrahedron Lett. 1995, 36, 3149-3152.
59. (b) Sasaki, N. A.; Sagnard, I. A Novel Method for Chirospecific Synthesis of 2,5-Disubstituted Pyrrolides. Tetrahedron 1994, 50, 7093-7108.
60. (c) Tverezovsky, V. V.; Baird, M. S.; Bolesov, I. G. Synthesis of (2S,3R,4S)-3,4-Methanoproline and Analogues by Cyclopropylidene Insertion. Tetrahedron 1997, 53, 14773-14792.
61. (a) Hercouet, A.; Bessieres, B.; Le Corre, M. First Asymmetric Synthesis of (-)-(2S,3R)-Methanoproline. Tetrahedron: Asymmetry 1996, 7, 1267-1268.
62. (b) Stammer, C. H.; Switzer, F. L.; Van Halbeek, H.; Holt, E. M. Synthesis of (±)-2,3-Methanoproline: A Novel Inhibitor of Ethylene Biosynthesis. Tetrahedron 1989, 45, 6091-6100.
63. (a) Grayson, I. Water-Soluble Carbodiimide-An Efficient Coupling Agent for Synthesis. Spec. Chem. 2000, 20, 86-88.
64. (b) Benoiton, N. L.; Kuroda, K. Studies on Racemization During Couplings Using a Series of Model Tripeptides Involving Activated Residues with Unfunctionalized Side Chains. Int. J. Pept. Protein Res. 1981, 17, 197-204.
65. (c) Hoeg-Jensen, T.; Havsteen J. M.; Holm, A. A New Method for Rapid Solution Synthesis of Shorter Peptides by Use of (Benzotriazolyloxy)tripyrrolidinophosphonium hexafluorophosphate (Py BOP). Tetrahedron Lett. 1991, 32, 6387-6390.
66. (d) Frerot, E.; Coste, J.; Pantaloni, A.; Dufour, M., N.; Jouin, P. PyBOP and PyBroP: Two Reagents for the Difficult Coupling of the α,α-Dialklylamino Acid, AIB. Tetrahedron 1991, 47, 259-270.
67. Stuber, W.; Kosina, H.; Heimburger, N. Synthesis of a Tripeptide with a C-Terminal Nitrile Moiety and the Inhibition of Proteinases. Int. J. Pept. Protein Res. 1988, 31, 63-70.
68. Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 2nd ed.; John Wiley & Sons: New York, 1991; pp 315-347.
69. 4/Base-III. Umsetzen Von Ketonen und α-Halogenketonen Mit Malonester (Conversion from Ketones and α-Halogen Ketones with Malonic Ester). Tetrahedron 1973, 29, 635-638.
70. (b) Holmberg, C. Synthese und Eigenschafter einiger tert-Alkylmalonsaurederivate (Synthesis of tert-Alkylmalonic Acid Derivatives). Leibigs Ann. Chem. 1981, 748-760.
71. (c) Yamada, S.-I.; Ninomiya, K.; Shioiri, T. Transfer of the Azido Function from Diphenylphophoryl Azide to Malonic Acid Half Esters. Tetrahedron Lett. 1973, 26, 2343-2346.
72. In cases where racemic Boc-protected amino acids were coupled to the enantiomerically pure 4,5-methanoproline nitriles, the latter-eluting isomer on silica gel chromatography (10-40% EtOAc-hexanes) consistently provided the L,L-diastereomer. The stereochemistry was established in several cases through single-crystal X-ray crystallography, though because this stereochemistry has correlated with inhibitory activity against DPP-IV (in this series and in prolinenitrile inhibitors published by others), the latter was typically used as confirmation of stereochemistry.
73. Ashworth, D. M.; Atrash, B.; Baker, G. R.; Baxter, A. J.; Jenkins, P. D. ; Jones, M. D.; Szelke, M. 4-Cyanothiazolidides as Very Potent, Stable Inhibitors of Dipeptidyl Peptidase IV. Bioorg. Med. Chem. Lett. 1996, 6, 2745-2748.
74. Snow, R. J.; Bachovchin, W. W.; Barton, R. W.; Campbell, S. J.; Coutts, S. J.; Freeman, D. M.; Gutheil, W. G.; Kelly, T. A.; Kennedy, C. A.; Krolikowski, D. A.; Leonard, S. F.; Pargellis, C. A.; Tong, L.; Adams, J. Studies on Proline Boronic Acid Dipeptide Inhibitors of Dipeptidyl Peptidase IV: Identification of a Cyclic Species Containing a B-N Bond. J. Am. Chem. Soc. 1994, 116, 10860-10869.
75. Crystallographic data (excluding structure factors) for the TFA salt of 29 have been deposited with the Cambridge Crystallographic Data Centre. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving. html (or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, U.K.; fax, +44 1223 336033; e-mail, deposit@ccdc.cam.ac.uk).
76. (a) Rasmussen, H. B.; Branner, S.; Wiberg, F. C.; Wagtmann, N. Crystal Structure of Human Dipeptidyl Peptidase IV/CD26 in Complex with a Substrate Analog. Nat. Struct. Biol. 2003, 10, 19-25.
77. (b) Engel, M.; Torsten, H.; Wagner, L.; Wermann, M.; Heiser, U.; Kiefersauer, R.; Huber, R.; Bode, W.; Demuth, H.-U.; Brandstetter, H. The Crystal Structure of Dipeptidyl Peptidase IV (CD26) Reveals Its Functional Regulation and Enzymatic Mechanism. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 5063-5068.
78. (c) Thoma, R.; Löffler, B.; Stihle, M.; Huber, W.; Ruf, A.; Hennig, M. Structural Basis of Proline-Specific Exopeptidase Activity as Observed in Human Dipeptidyl Peptidase-IV. Structure 2003, 11, 947-959.
79. (d) Oefner, C.; D'Arcy, A.; MacSweeney, A.; Pireau, S.; Gardiner, R.; Dale, G. E. High Resolution Structure of Human Apo Dipeptidyl Peptidase IV/CD26 and Its Complex with 1-[({2-[(5-Iodopyridin-2-yl)amino]ethyl}amino)acetyl]-2-cyano-(S)-pyrrolidine. Acta Crystallogr. 2003, D59, 1206-1212.
80. (e) Hiramatsu, H.; Kyono, K.; Higashiyama, Y.; Fukushima, C.; Shima, H.; Sugiyama, S.; Inaka, K.; Yamamoto, A.; Shimizu, R. The Structure and Function of Human Dipeptidyl Peptidase IV, Possessing a Unique Eight-Bladed Beta-Propeller Fold. Biochem. Biophys. Res. Commun. 2003, 302, 849-854.
81. 3-CN: Aray, Y.; Murgich, J. Nucleophilic Attack on the Cyano Group: A Description in Terms of the Laplacian of the Molecular Charge Density. THEOCHEM 1993, 106, 229-233.
82. 3-CN: Aray, Y.; Murgich, J. Nucleophilic Attack on the Cyano Group: A Description in Terms of the Laplacian of the Molecular Charge Density. THEOCHEM 1993, 106, 229-233.
83. (a) Holst, J. J.; Deacon, C. F. Inhibition of the Activity of Dipeptidyl-Peptidase IV as a Treatment for Type 2 Diabetes. Diabetes 1998, 47, 1663-1670.
84. (b) Balkan, B.; Kwansnik, L.; Miserendino, R.; Holst, J. J.; Li, X. Inhibition of Dipeptidyl Peptidase IV with NVP-DPP728 Increases Plasma GLP-1 (7-36) Amide Concentrations and Improves Oral Glucose Tolerance in Obese Zucker Rats. Diabetologia 1999, 42 (11), 1324-1331.
85. (c) Rothenberg, P.; Kalbag, J.; Smith, H. T.; Gingerich, R.; Nedelman, J.; Villhauer, E.; McLeod, J.; Hughes, T. Treatment with a DPP-IV Inhibitor, NVP-DPP728, Increases Prandial Intact GPL-1 Levels and Reduces Glucose Exposure in Humans. Diabetes 2000, 49 (1), A39.
86. Truett, G.; Bahary, N.; Friedman, J. M.; Leibel, R. L. The Zucker Rat Obesity Gene Fatty (fa) Maps to Chromosome 5 and Is a Homologue of the Mouse Diabetes (db) Gene. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 7806-7809.
87. Pederson, R. A.; White, H. A.; Schlenzig, D.; Pauly, R. P.; McIntosh, C. H.; Demuth, H. U. Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide. Diabetes 1998, 47, 1253-1258.
88. Maestro, version 4.1.012, and Mmshare, version 1.0.067; Schrodinger, Inc.: Portland, OR, 1999-2001.
89. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Zakrzewski, V. G.; Montgomery, J. A., Jr.; Stratmann, R. E.; Burant, J. C.; Dapprich, S.; Millam, J. M.; Daniels, A. D.; Kudin, K. N.; Strain, M. C.; Farkas, O.; Tomasi, J.; Barone, V.; Cossi, M.; Cammi, R.; Mennucci, B.; Pomelli, C.; Adamo, C.; Clifford, S.; Ochterski, J.; Petersson, G. A.; Ayala, P. Y.; Cui, Q.; Morokuma, K.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Cioslowski, J.; Ortiz, J. V.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Gonzalez, C.; Challacombe, M.; Gill, P. M. W.; Johnson, B. G.; Chen, W.; Wong, M. W.; Andres, J. L.; Head-Gordon, M.; Replogle, E. S.; Pople, J. A. Gaussian 98, revision A.6; Gaussian, Inc.: Pittsburgh, PA, 1998.
90. Insight II, version 2000; Molecular Simulations Inc.: San Diego, CA, 2000.
91. Wang, A.; Huang, Y.; Taunk, P.; Magnin, D. R.; Ghosh, K.; Robertson, J. G. Application of Robotics to Steady State Enzyme Kinetics: Analysis of Tight-Binding Inhibitors of Dipeptidyl Peptidase IV. Anal. Biochem. 2003, 321, 157-166.